Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of karyosome protein SP110 and kit containing karyosome protein SP110 to preparation of early diagnosis reagent for alcoholic cardiomyopathy

An alcoholic cardiomyopathy and nuclear protein technology, applied in the field of medicine, can solve the problem that the diagnosis of alcoholic cardiomyopathy cannot achieve early high sensitivity and high specificity, and cannot achieve early high sensitivity and high specificity of alcoholic cardiomyopathy. Diagnose and other problems to achieve highly specific results

Active Publication Date: 2018-12-11
HARBIN MEDICAL UNIVERSITY
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows for accurate detection of autoantigens (anti-S100) by measuring their levels in blood samples from people who have been exposed to these substances or taking them out over time. By comparing this data against previous results it can help identify individuals at risk that may be experiencing an illness such as Alcohols Cardiovascular Disease ("ACC").

Problems solved by technology

This patented technical problem addressed in this patents relates to finding reliable markers or biochemistry targets on an individual basis during their lifetime due to chronotropic cerebrum disease called ACML which affects about 20% of individuals throughout Western Europe and North America. Current therapy options involve drugs like beta blocker agents used alone but they cannot accurately predict if these treatments could prevent further decline in CHE risk compared to non-tranvasively treated cases. There is thus a pressing need for new biological indicators capable of earlier accurate identification of ACMI without causing significant side effects when administered late.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of karyosome protein SP110 and kit containing karyosome protein SP110 to preparation of early diagnosis reagent for alcoholic cardiomyopathy
  • Application of karyosome protein SP110 and kit containing karyosome protein SP110 to preparation of early diagnosis reagent for alcoholic cardiomyopathy
  • Application of karyosome protein SP110 and kit containing karyosome protein SP110 to preparation of early diagnosis reagent for alcoholic cardiomyopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1 Determination of Candidate Serum Biomarkers

[0044] The present invention utilizes the advantages of high-throughput and rapid analysis of the human proteome chip to analyze 120 serums related to alcoholic cardiomyopathy patients (40 serums from alcoholic cardiomyopathy patients, 20 serums from DCM patients, and 60 serums from healthy people). The differences in the samples of alcoholic cardiomyopathy patients, DCM patients and healthy people were compared, and it was found that the expression level of nuclear body protein Sp110 (Q9HB58-SP110_HUMAN) was significantly higher in alcoholic cardiomyopathy patients than in DCM patients and healthy people. It is suggested that nuclear body protein Sp110 can be used as a candidate serum biomarker of alcoholic cardiomyopathy for early diagnosis and effective treatment of ACM.

Embodiment 2

[0045] Example 2 Application of nucleosomal protein Sp110 in the diagnosis of alcoholic cardiomyopathy

[0046] 1. Expression, purification and identification of nuclear protein Sp110

[0047] Human ribosomal protein Sp110 (Q9HB58-SP110_HUMAN, containing 689 amino acids, 78.4KDa) is isolated and purified by agarose affinity medium (glutathione) after overexpression induced by genetically engineered Saccharomyces cerevisiae And obtain, carry out the result of silver staining quantification and Western-Blotting identification to it respectively as follows figure 1 and figure 2 shown.

[0048] 2. Preparation of serum samples:

[0049] Whole blood samples should be left at room temperature for 2 hours, centrifuged at 2000g for about 5 minutes, and the supernatant can be taken for immediate detection; or aliquoted, and the samples should be stored at -20°C or -80°C, but repeated freezing and thawing should be avoided. Thawed samples should be centrifuged again prior to testing...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of a karyosome protein SP110 and a kit containing the karyosome protein SP110 to the preparation of an early diagnosis reagent for alcoholic cardiomyopathy (ACM). Found by analyzing related blood serum of a patient suffering from the ACM by virtue of the advantages of high throughput and high analysis speed of a human proteome chip and comparing the differences of samples of the patient suffering from the ACM, a patient suffering from dilated cardiomyopathy (DCM) and a healthy person within relatively short time, the expression level of the karyosome protein SP110 in the patient suffering from the ACM is obviously higher than that of each of the patient suffering from the DCM and the healthy person, which hints that the karyosome protein SP110 can beused as a candidate blood serum biomarker of the ACM to realize early diagnosis of the ACM. Experiments prove that the blood serum marker SP110 provided by the invention has the specificity of 80% andthe sensibility of 82% and has the characteristics of high specificity and high sensibility. Further, the invention provides a commercial kit which is sensitive, safe, reliable and easy to operate, and the commercial kit can be used for qualitatively testing the level of IgM antibodies resisting to SP110 in the human blood serum and is beneficial to the early diagnosis of the ACM.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com